title: Prolonged efficacy of infliximab for refractory adult-onset Still's disease.
authors.forename: M S
authors.initials: MS
authors.lastname: Dilhuydy
authors.forename: R
authors.initials: R
authors.lastname: Vatan
authors.forename: G
authors.initials: G
authors.lastname: Etienne
authors.forename: M
authors.initials: M
authors.lastname: Longy-Boursier
authors.forename: P
authors.initials: P
authors.lastname: Mercié
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab; D016706:Still's Disease, Adult-Onset / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab